HighTower Advisors
AUXL

HighTower Advisors’s AUXILIUM PHARAMCEUTICALS INC AUXL Stock Holding History

HighTower Advisors’s Portfolio AUXL Stock Details AUXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-11,610
Closed -$316K – 1776
2014
Q1 		$316K Buy
+11,610
New +$308K 0.01% 1151

Other funds holding AUXL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

HighTower Advisors's AUXL Position: Q2 2014 in Review

HighTower Advisors sold out of AUXILIUM PHARAMCEUTICALS INC (AUXL) in Q2 2014, closing a stake of 11,610 shares — an estimated $316K sold.

HighTower Advisors first reported a position in AUXL in Q1 2014 and held it in 1 quarter. The position peaked at $316K in Q1 2014. 152 funds tracked by Wall St. Rank hold AUXL as of Q2 2014.

  • HighTower Advisors reported no remaining AUXILIUM PHARAMCEUTICALS INC position as of Q2 2014 after selling out during the quarter.
  • HighTower Advisors sold 11,610 AUXILIUM PHARAMCEUTICALS INC shares in Q2 2014, an estimated $316K.
  • HighTower Advisors first reported a position in AUXILIUM PHARAMCEUTICALS INC in Q1 2014 and held it in 1 quarter.
  • HighTower Advisors's AUXILIUM PHARAMCEUTICALS INC position peaked at $316K in Q1 2014.
  • 152 funds tracked by Wall St. Rank held AUXILIUM PHARAMCEUTICALS INC as of Q2 2014.

Based on HighTower Advisors's 13F filing for Q2 2014, filed 13 Aug 2014.